ZYDUS LIFESCIENCES LIMITED

Business Segments Zydus Lifesciences Limited

Equities

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:05:05 2026-03-09 am EDT			5-day change	1st Jan Change
908.85 ^INR	-0.46%		+0.22%	-0.60%

Feb. 28	Zydus Lifesciences Limited Receives Final Approvals from USFDA for Ivermectin Tablets USP, 3 Mg and Dapsone Tablets USP, 25 Mg and 100 Mg	CI
Feb. 27	Zydus Lifesciences says successful clinical development of pembrolizumab biosimilar fyb206	RE

Sales 2025 by Business Segment

© MarketScreener.com See more

Sales 2025 by Geography

© MarketScreener.com See more

Historical Breakdown of Revenue by Business Segments

EBT: Breakdown by Business Segment

Breakdown by Business Segment (INR)

Fiscal Period: March	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Medicinal Chemicals and Botanical Products
Pharmaceuticals						133B	133B	150B	172B	205B
Total Assets						182B	221B	199B	231B	308B
Interest Expense						-	-	-	-	-
Income Tax Expense						-	-	-	-	-
CAPEX						-	-	-	-	-
EBT						22.46B	24.19B	28.93B	45.57B	58.99B
D&A						-	-	-	-	-
Net Income						-	-	-	-	-
Pharmaceutical Products
Consumer Products						18.41B	19.79B	22.45B	23.12B	26.98B
Total Assets						56.66B	56.92B	58.33B	61.46B	64.39B
EBT						2.44B	3.06B	3.01B	2.66B	3.47B

Geographical Revenue Distribution History

Geographical breakdown of sales (INR)

Fiscal Period: March	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
United States						65.44B	59.49B	74.87B	87.75B	111B
Total Assets						12.03B	8.97B	3.56B	3.92B	6.81B
CAPEX						-	-	-	-	-
India						64.62B	72.53B	76.4B	80.15B	92.53B
Total Assets						112B	115B	118B	139B	147B
CAPEX						-	-	-	-	-
Others						20.96B	20.63B	21.11B	27.57B	28.47B
Total Assets						4.8B	4.94B	5.16B	4.86B	3.97B
CAPEX						-	-	-	-	-

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!

BENEFIT NOW